Literature DB >> 16366168

[Prothrombotic state in early stages of chronic Chagas' disease. Its association with thrombotic risk factors].

Ramón N Herrera1, Elba Díaz, Rossana Pérez Aguilar, Jorge Bianchi, Sofía Berman, Héctor L Luciardi.   

Abstract

OBJECTIVE: The aim of this study was to explore the presence of prothrombotic state in early stages of chronic Chagas' disease with serum markers of thrombosis and fibrinolysis, and to investigate it's association with thrombotic risk factors for venous thromboembolic disease. PATIENTS AND METHODS: Forty two patients with chronic Chagas' disease were compared with 21 healthy volunteers. Thrombotic markers used were fragment 1 + 2, ATM complex, fibrinogen/fibrin degradation products, D-dimer and beta-thromboglobulin. Fibrinolysis was evaluated with euglobulin lysis time, tissue plasminogen activator and it's inhibitor levels. A thrombophilic screening was performed. Antithrombin and protein C were determined by functional methods, as well as free fraction of protein S, resistance to activated protein C, factor V Leiden R506Q mutation, prothrombin G20210A mutation, homocysteine and antiphospholipid antibodies: lupus and anticardiolipin antibodies isoforms IgG and IgM.
RESULTS: In chronic Chagas' disease patients, statistically significant differences were observed in thrombotic markers: fragment 1 + 2 (p < 0.0001), ATM complex (p < 0.0001), fibrinogen/fibrin degradation products (p < 0.05) and D-dimer (p < 0.05). beta-thromboglobulin did not reach statistically significant difference (p = 0.06). Statistically significant differences (p < 0.0001) were found only in euglobulin lysis time, a non specific fibrinolytic marker. Specific fibrinolytic markers tissue plasminogen activator and it's inhibitor, however, did not show statistically significant differences among studied groups.
CONCLUSIONS: Eighty six percent of patients had positive thrombophilic screening for at least one thrombophilic risk factor. Thrombophilic risk factors were inherited in 39% and acquired in 83% of the patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16366168

Source DB:  PubMed          Journal:  Arch Cardiol Mex        ISSN: 1665-1731


  5 in total

1.  Serum proteomic signature of human chagasic patients for the identification of novel potential protein biomarkers of disease.

Authors:  Jian-Jun Wen; M Paola Zago; Sonia Nuñez; Shivali Gupta; Federico Nuñez Burgos; Nisha Jain Garg
Journal:  Mol Cell Proteomics       Date:  2012-04-27       Impact factor: 5.911

Review 2.  Re. Re.: "Immunothrombotic dysregulation in Chagas disease and COVID19: a comparative study of anticoagulation".

Authors:  Laura Pérez-Campos Mayoral; María Teresa Hernández-Huerta; Eduardo Pérez-Campos Mayoral; Carlos Alberto Matias Cervantes; Eduardo Pérez-Campos
Journal:  Mol Cell Biochem       Date:  2022-07-13       Impact factor: 3.842

3.  Altered Hypercoagulability Factors in Patients with Chronic Chagas Disease: Potential Biomarkers of Therapeutic Response.

Authors:  Maria-Jesus Pinazo; Elizabeth de Jesus Posada; Luis Izquierdo; Dolors Tassies; Alexandre-Ferreira Marques; Elisa de Lazzari; Edelweiss Aldasoro; Jose Muñoz; Alba Abras; Silvia Tebar; Montserrat Gallego; Igor Correia de Almeida; Joan-Carles Reverter; Joaquim Gascon
Journal:  PLoS Negl Trop Dis       Date:  2016-01-04

4.  Impaired frequencies and function of platelets and tissue remodeling in chronic Chagas disease.

Authors:  Claudia Pengue; Gonzalo Cesar; María Gabriela Alvarez; Graciela Bertocchi; Bruno Lococo; Rodolfo Viotti; María Ailén Natale; Melisa D Castro Eiro; Silvia S Cambiazzo; Nancy Perroni; Myriam Nuñez; María Cecilia Albareda; Susana A Laucella
Journal:  PLoS One       Date:  2019-06-14       Impact factor: 3.240

5.  Oral Route Driven Acute Trypanosoma cruzi Infection Unravels an IL-6 Dependent Hemostatic Derangement.

Authors:  Dina Antunes; Alessandro Marins-Dos-Santos; Mariana Tavares Ramos; Barbara Angelica S Mascarenhas; Carlos José de Carvalho Moreira; Désio Aurélio Farias-de-Oliveira; Wilson Savino; Robson Q Monteiro; Juliana de Meis
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.